Understanding HYMPAVZI™ (marstacimab-hncq): A New Era in Bypassing Agents

In this session, we will cover some high-level information on what HYMPAVZI is and how it works.

Join us for an insightful session exploring HYMPAVZI, the newly FDA-approved bypassing agent making waves in the bleeding disorders community. We’ll break down what HYMPAVZI is, how it works in the body, and what makes it different from other treatment options. Whether you’re a patient, caregiver, or healthcare provider, this is your chance to get up to speed on this important advancement and what it could mean for managing your bleeding disorder. 

Speaker:

Bradley Schoenfeld, Advocacy and Community Engagement Director, Pfizer

Brad serves as advocacy and community engagement team lead within Pfizer's U.S. Rare Disease Patient Affairs unit. Prior to joining Pfizer in 2020, he served as President, New York City Hemophilia Chapter (NYCHC). In 2017, he received the Award of Distinction presented at its annual Gala. In 2013, Brad was the recipient of the Award of Excellence by the National Hemophilia Foundation (now National Bleeding Disorders Foundation). Of note, in 2010, Brad formulated the marketing strategy, creative directed the poster design, served as publicist and helped to form a distribution collaboration with Gay Men’s Health Crisis (now GMHC) and PBS, all in support of the documentary feature “Bad Blood: A Cautionary Tale.”